ClinicalTrials.gg
CompletedNCT00745901Updated Mar 19, 2019Results posted

Study to Evaluate Cycle Control With Norgestimate/Ethinyl Estradiol and Drospirenone/Ethinyl Estradiol in Healthy Sexually Active Females

A Phase 4 interventional study of Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol in Contraception, sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC. Completed. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-19.

Sponsored by Ortho-McNeil Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
355
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Hemorrhage by Johnson & Johnson — 1 open to participants now, 1 under way, none of them phase 3. Hemorrhage · Johnson & Johnson.

Enrollment
2nd of 13
355 · median 150
Started
2008
the only one that year
Phase 4
3 of 16
none open now
Registered
3rd of 16
by date

Among the 16 studies in Hemorrhage by Johnson & Johnson, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 4, and was the 3rd registered.

Hemorrhage

1,384 studies on the registry are indexed under Hemorrhage; 245 are open to participants now.

Browse Hemorrhage studies →

Open to participants now

1 of the 16 studies in Hemorrhage by Johnson & Johnson is open now. Recruiting first, the newest first:

Who these studies take

Of the 171 Hemorrhage studies recruiting now, 109 (64%) set no upper age limit and 41 (24%) stop at 75 or younger; 26 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hemorrhage by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study in healthy sexually active females is to evaluate the cycle control with norgestimate/ethinyl estradiol versus drospirenone/ethinyl estradiol.

Read the detailed description

This is a randomized, open-label, active-controlled, multicenter study in healthy sexually active females to evaluate cycle control with norgestimate/ethinyl estradiol versus drospireneone/ethinyl estradiol. The Open-Label Treatment Phase will last for three 28-day cycles. Approximately 300 patients will be randomized in a 1:1 fashion according to a predetermined randomization schedule. Patients will be seen for a baseline visit (Visit 1) up to 35 days prior to dosing to obtain informed consent, have a physical examination including a breast exam, height and weight, vital signs, a Chlamydia test and a urine pregnancy test performed, and to give their medical history. Patients will be instructed to report bleeding data using an interactive voice response system (IVRS) based diary on a daily basis. Patients will be instructed to continue taking 1 pill each day for 3 cycles, record this information daily in the IVRS and to contact the study site if they have any questions or adverse events they would like to discuss. The final study visit (Visit 2) will occur on Day 8 after completing 3 cycles of study medication. Patients will be weighed, have vital signs performed, report any adverse events and or changes in concomitant medications, and complete the satisfaction questionnaire at the final visit. Safety will be assessed by physical examinations, adverse events, body weight and vital signs. Patients randomized to drospireneone/ethinyl estradiol and taking any medication that could increase serum potassium levels (as outlined in the Package Insert) will also have their potassium level checked during their first cycle of treatment (Days 15 to 28 of treatment). Three 28-day cycles of either norgestimate/ethinyl estradiol or drospirenone/ethinyl estradiol.

03

Conditions studied

  • Contraception

Browse trials for

Keywords

  • contraception
  • bleeding
  • cycle control
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy females who want oral
  • No cervical or vaginal abnormalities on gynecological examination
  • Negative Chlamydia test
  • Pap smear without evidence of moderate or severe dysplasia or any within the preceding 12 months
  • Negative urine pregnancy test conducted during Visit 1
  • One normal menstrual period in 35 days prior to Visit 1
  • Regular menstrual cycles (every 26-35 days)
  • Last term pregnancy at least 42 days prior to Visit 1, and have had at least one normal menstrual period (typical in duration and amount of flow for the subject) since her last pregnancy
  • Post-menarcheal and pre-menopausal
  • At least one normal menstrual period (typical in duration and amount of flow for the subject) since having undergone uterines urgery or removal of an IUD, Norplant, DepoProvera or other hormonal injectables or implants.

Exclusion criteria

Exclusion Criteria:

  • History or presence of disorders commonly accepted as to hormonal therapy
  • Previously discontinued ORTHO TRI-CYCLEN LO or YAZ due to breakthrough bleeding
  • Pregnant or lactating
  • (BMI) of >40kg/m2
  • Clinical evidence of carcinoma or other (history of basal cell carcinoma of the skin is not exclusionary)
  • History of alcohol or drug abuse in the investigator's judgment based on history and physical examination (within 12 months prior to Visit 1)
  • Significant depression or psychiatric disease in the investigator's judgment based on history and physical examination which would result in an unreliable patient
  • Patient deemed by the investigator to have questionable reliability in her ability to comply with the protocol and provide accurate information
  • Have any medical condition or planned surgical procedure which, in the opinion of the investigator, may be exacerbated by treatment with study medication or a patient receiving any concurrent therapy that could be affected by treatment with study medication
  • Disallowed therapies: currently taking therapeutic anticoagulants (e.g,. Coumadin, Heparin) or have a bleeding disorder (e.g. von Willebrand's Disease), DepoProvera or other hormonal injectables in the six months before Visit 1, currently have Norplant or other hormonal implants in place, or have had removal of Norplant within 60 days prior to Visit 1, used a steroid-containing IUD within 3 months prior to Visit 1
  • Or current use of an IUD
  • Consistently elevated blood pressure defined as sitting systolic BP>140 mmHg or diastolic BP>90 mmHg
  • Have an untreated thyroid disorder in the investigator's judgment based on history and physical examination
  • unable to swallow solid, oral dosage forms whole with the aid of water (participants may not chew, divide, dissolve, or crush the study drug)
  • Patients who in the opinion of the investigator should not be enrolled in the study based on the product labeling for ORTHO TRI-CYCLEN LO and YAZ including potential drug-drug interactions
  • Have received an experimental drug or used an experimental medical device within 30 days before the planned start of treatment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
355 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Days of Unscheduled Blood Loss - Cycle 1

    cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

    Time frame: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)

  2. Number of Days of Unscheduled Blood Loss - Cycle 2

    cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

    Time frame: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)

  3. Number of Days of Unscheduled Blood Loss - Cycle 3

    Number of Days of Unscheduled Blood Loss - Cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

    Time frame: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)

  4. Overall Number of Days of Unscheduled Blood Loss

    cycle control between treatment groups, for three 28-day cycles. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

    Time frame: Cycle 1 to Cycle 3 (Day 8 to Day 80)

  5. Number of Participants With the Indicated Number of Unscheduled Blood Loss Episodes

    Unscheduled blood loss episodes are bounded on both sides by at least 1 non- bleeding day.

    Time frame: Cycle 1 to Cycle 3 (Day 8 to Day 80)

  6. Number of Days of Scheduled Blood Loss - Cycle 1

    cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.

    Time frame: Cycle 1 (Day 22 to 32 for NGM/25mcg EE and day 25 to 32 for DRSP/20mcg EE)

  7. Number of Days of Scheduled Blood Loss - Cycle 2

    cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.

    Time frame: Cycle 2 (Day 50 to 60 for NGM/25mcg EE and day 53 to 60 for DRSP/20mcg EE)

  8. Number of Days of Scheduled Blood Loss - Cycle 3

    cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.

    Time frame: Cycle 3 (Day 78 to 84 for NGM/25mcg EE and day 81 to 84 for DRSP/20mcg EE)

  9. Overall Number of Days of Scheduled Blood Loss

    summary of the overall number of days of scheduled blood loss. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.

    Time frame: Cycle 1 to Cycle 3 (Day 8 to Day 84)

  10. Number of Days of Total Blood Loss - Cycle 1

    cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.

    Time frame: Cycle 1 (Day 8 to Day 28)

  11. Number of Days of Total Blood Loss - Cycle 2

    cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.

    Time frame: Cycle 2 (day 29 to Day 56)

  12. Number of Days of Total Blood Loss - Cycle 3

    cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.

    Time frame: Cycle 3 (Day 57 to Day 84)

  13. Overall Number of Days of Total Blood Loss

    cycle control between treatment groups, overall. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.

    Time frame: Cycle 1 to 3 (Day 8 to Day 84)

  14. Number of Participants With Unscheduled Bleeding Cycle 1

    Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

    Time frame: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)

  15. Number of Participants With Unscheduled Bleeding Cycle 2

    Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

    Time frame: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)

  16. Number of Participants With Unscheduled Bleeding Cycle 3

    Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

    Time frame: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)

  17. Number of Participants With Breakthrough Bleeding/Spotting Cycle 1

    Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding.

    Time frame: Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)

  18. Number of Participants With Breakthrough Bleeding/Spotting Cycle 2

    Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding.

    Time frame: Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)

  19. Number of Participants With Breakthrough Bleeding/Spotting Cycle 3

    Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

    Time frame: Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)

Secondary outcomes

  1. Patient Satisfaction - Overall

    patient satisfaction based on 5 questions during three 28-day cycles - Question 1 (Overall Satisfaction). On a scale of 1 to 5 where 1=Very satisfied and 5=Very dissatisfied.

    Time frame: Cycle 1 to Cycle 3

07

Results

Posted May 25, 2010

Participant flow

Participant flow — Overall Study
MilestoneNGM/25mcg EEDRSP/20mcg EE
Started178177
Completed154156
Not completed2421
Withdrew: Adverse event34
Withdrew: Protocol violation01
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up74
Withdrew: Pregnancy24
Withdrew: Lack of compliance22
Withdrew: Patient's next menses did not start with10
Withdrew: Results of pap smear at vis 1 malignant02
Withdrew: Chlamydia test at visit 1 was positive11
Withdrew: Patient didn't take any study medication73

Outcome measures

PrimaryNumber of Days of Unscheduled Blood Loss - Cycle 1

cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

Time frame:
Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)
Reported as:
Mean · Days
Number of Days of Unscheduled Blood Loss - Cycle 1
DaysNGM/25mcg EEDRSP/20mcg EE
Number of Days of Unscheduled Blood Loss - Cycle 11.9 ± 3.142.0 ± 3.53
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = 0.9698
SecondaryPatient Satisfaction - Overall

patient satisfaction based on 5 questions during three 28-day cycles - Question 1 (Overall Satisfaction). On a scale of 1 to 5 where 1=Very satisfied and 5=Very dissatisfied.

Time frame:
Cycle 1 to Cycle 3
Reported as:
Number · Participants
Patient Satisfaction - Overall
ParticipantsNGM/25mcg EEDRSP/20mcg EE
Number of responses159162
1. Very Satisfied99115
2. Somewhat satisfied3532
3. Neither satisfied or dissatisfied126
4. Dissatisfied118
5. Very dissatisfied21
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = 0.0715
PrimaryNumber of Days of Unscheduled Blood Loss - Cycle 2

cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

Time frame:
Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)
Reported as:
Mean · Days
Number of Days of Unscheduled Blood Loss - Cycle 2
DaysNGM/25mcg EEDRSP/20mcg EE
Number of Days of Unscheduled Blood Loss - Cycle 21.3 ± 2.491.9 ± 2.86
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = 0.0050
PrimaryNumber of Days of Unscheduled Blood Loss - Cycle 3

Number of Days of Unscheduled Blood Loss - Cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

Time frame:
Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)
Reported as:
Mean · Days
Number of Days of Unscheduled Blood Loss - Cycle 3
DaysNGM/25mcg EEDRSP/20mcg EE
Number of Days of Unscheduled Blood Loss - Cycle 31.4 ± 2.332.4 ± 2.86
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = 0.0006
PrimaryOverall Number of Days of Unscheduled Blood Loss

cycle control between treatment groups, for three 28-day cycles. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

Time frame:
Cycle 1 to Cycle 3 (Day 8 to Day 80)
Reported as:
Mean · Days
Overall Number of Days of Unscheduled Blood Loss
DaysNGM/25mcg EEDRSP/20mcg EE
Overall Number of Days of Unscheduled Blood Loss4.6 ± 5.336.1 ± 6.07
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = 0.0031
PrimaryNumber of Participants With the Indicated Number of Unscheduled Blood Loss Episodes

Unscheduled blood loss episodes are bounded on both sides by at least 1 non- bleeding day.

Time frame:
Cycle 1 to Cycle 3 (Day 8 to Day 80)
Reported as:
Number · Participants
Number of Participants With the Indicated Number of Unscheduled Blood Loss Episodes
ParticipantsNGM/25mcg EEDRSP/20mcg EE
0 Episode5529
1 Episode4641
2 Episodes2350
3 Episodes2122
4 Episodes1311
5 Episodes78
6 Episodes02
8 Episodes03
9 Episodes01
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = 0.0013
PrimaryNumber of Days of Scheduled Blood Loss - Cycle 1

cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.

Time frame:
Cycle 1 (Day 22 to 32 for NGM/25mcg EE and day 25 to 32 for DRSP/20mcg EE)
Reported as:
Mean · Days
Number of Days of Scheduled Blood Loss - Cycle 1
DaysNGM/25mcg EEDRSP/20mcg EE
Number of Days of Scheduled Blood Loss - Cycle 14.3 ± 2.093.2 ± 2.35
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = <0.0001
PrimaryNumber of Days of Scheduled Blood Loss - Cycle 2

cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.

Time frame:
Cycle 2 (Day 50 to 60 for NGM/25mcg EE and day 53 to 60 for DRSP/20mcg EE)
Reported as:
Mean · Days
Number of Days of Scheduled Blood Loss - Cycle 2
DaysNGM/25mcg EEDRSP/20mcg EE
Number of Days of Scheduled Blood Loss - Cycle 24.0 ± 2.152.8 ± 2.40
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = <0.0001
PrimaryNumber of Days of Scheduled Blood Loss - Cycle 3

cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.

Time frame:
Cycle 3 (Day 78 to 84 for NGM/25mcg EE and day 81 to 84 for DRSP/20mcg EE)
Reported as:
Mean · Days
Number of Days of Scheduled Blood Loss - Cycle 3
DaysNGM/25mcg EEDRSP/20mcg EE
Number of Days of Scheduled Blood Loss - Cycle 33.1 ± 2.091.2 ± 1.30
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = <0.0001
PrimaryOverall Number of Days of Scheduled Blood Loss

summary of the overall number of days of scheduled blood loss. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity. Scheduled bleeding was defined as any bleeding that occurred while not taking active hormones, regardless of the duration of regimen.

Time frame:
Cycle 1 to Cycle 3 (Day 8 to Day 84)
Reported as:
Mean · Days
Overall Number of Days of Scheduled Blood Loss
DaysNGM/25mcg EEDRSP/20mcg EE
Overall Number of Days of Scheduled Blood Loss11.2 ± 5.407.0 ± 4.80
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = <0.0001
PrimaryNumber of Days of Total Blood Loss - Cycle 1

cycle control between treatment groups, cycle 1. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.

Time frame:
Cycle 1 (Day 8 to Day 28)
Reported as:
Mean · Days
Number of Days of Total Blood Loss - Cycle 1
DaysNGM/25mcg EEDRSP/20mcg EE
Number of Days of Total Blood Loss - Cycle 16.2 ± 3.885.2 ± 4.45
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = 0.0033
PrimaryNumber of Days of Total Blood Loss - Cycle 2

cycle control between treatment groups, cycle 2. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.

Time frame:
Cycle 2 (day 29 to Day 56)
Reported as:
Mean · Days
Number of Days of Total Blood Loss - Cycle 2
DaysNGM/25mcg EEDRSP/20mcg EE
Number of Days of Total Blood Loss - Cycle 25.3 ± 2.664.6 ± 3.25
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = 0.0060
PrimaryNumber of Days of Total Blood Loss - Cycle 3

cycle control between treatment groups, cycle 3. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.

Time frame:
Cycle 3 (Day 57 to Day 84)
Reported as:
Mean · Days
Number of Days of Total Blood Loss - Cycle 3
DaysNGM/25mcg EEDRSP/20mcg EE
Number of Days of Total Blood Loss - Cycle 34.6 ± 2.643.6 ± 3.10
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = <0.0001
PrimaryOverall Number of Days of Total Blood Loss

cycle control between treatment groups, overall. Cycle control includes number of days of blood loss, incidence of blood loss, number of blood loss episodes, and blood loss flow intensity.

Time frame:
Cycle 1 to 3 (Day 8 to Day 84)
Reported as:
Mean · Days
Overall Number of Days of Total Blood Loss
DaysNGM/25mcg EEDRSP/20mcg EE
Overall Number of Days of Total Blood Loss15.8 ± 6.5813.2 ± 6.90
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Wilcoxon (Mann-Whitney) · p = <0.0001
PrimaryNumber of Participants With Unscheduled Bleeding Cycle 1

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

Time frame:
Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)
Reported as:
Number · Participants
Number of Participants With Unscheduled Bleeding Cycle 1
ParticipantsNGM/25mcg EEDRSP/20mcg EE
Number of Participants With Unscheduled Bleeding Cycle 17274
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Fisher Exact · p = 0.912
PrimaryNumber of Participants With Unscheduled Bleeding Cycle 2

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

Time frame:
Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)
Reported as:
Number · Participants
Number of Participants With Unscheduled Bleeding Cycle 2
ParticipantsNGM/25mcg EEDRSP/20mcg EE
Number of Participants With Unscheduled Bleeding Cycle 25787
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Fisher Exact · p = 0.003
PrimaryNumber of Participants With Unscheduled Bleeding Cycle 3

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

Time frame:
Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)
Reported as:
Number · Participants
Number of Participants With Unscheduled Bleeding Cycle 3
ParticipantsNGM/25mcg EEDRSP/20mcg EE
Number of Participants With Unscheduled Bleeding Cycle 36594
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Fisher Exact · p = 0.002
PrimaryNumber of Participants With Breakthrough Bleeding/Spotting Cycle 1

Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding.

Time frame:
Cycle 1 (Day 8 to 21 for NGM/25mcg EE and day 8 to 24 for DRSP/20mcg EE)
Reported as:
Number · Participants
Number of Participants With Breakthrough Bleeding/Spotting Cycle 1
ParticipantsNGM/25mcg EEDRSP/20mcg EE
Number of Participants With Breakthrough Bleeding/Spotting Cycle 15356
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Fisher Exact · p = 0.816
PrimaryNumber of Participants With Breakthrough Bleeding/Spotting Cycle 2

Breakthrough bleeding/spotting is any bleeding or spotting during active pills excluding days contiguous with withdrawal bleeding or continual withdrawal bleeding.

Time frame:
Cycle 2 (Day 29 to 49 for NGM/25mcg EE and day 29 to 52 for DRSP/20mcg EE)
Reported as:
Number · Participants
Number of Participants With Breakthrough Bleeding/Spotting Cycle 2
ParticipantsNGM/25mcg EEDRSP/20mcg EE
Number of Participants With Breakthrough Bleeding/Spotting Cycle 23962
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Fisher Exact · p = 0.012
PrimaryNumber of Participants With Breakthrough Bleeding/Spotting Cycle 3

Unscheduled bleeding is any bleeding during active pills except days 1-4 of cycle 2 or 3 if contiguous with withdrawal bleeding and days 1-7 of the first cycle.

Time frame:
Cycle 3 (Day 57 to 77 for NGM/25mcg EE and day 57 to 80 for DRSP/20mcg EE)
Reported as:
Number · Participants
Number of Participants With Breakthrough Bleeding/Spotting Cycle 3
ParticipantsNGM/25mcg EEDRSP/20mcg EE
Number of Participants With Breakthrough Bleeding/Spotting Cycle 34774
Statistical analysis
  • NGM/25mcg EE vs DRSP/20mcg EE · Fisher Exact · p = 0.003

Adverse events

Collected over 35 days prior to the first day study drug was taken to study day 91 (or 7 days after last day of study drug). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NGM/25mcg EE—2/167 (1.2%)34/167 (20.4%)
DRSP/20mcg EE—1/167 (0.6%)34/167 (20.4%)
Most frequent serious events
Most frequent serious events
EventNGM/25mcg EEDRSP/20mcg EE
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/1670/167
Ovarian cyst rupturedReproductive system and breast disorders1/1670/167
Pelvic hemorrhageReproductive system and breast disorders1/1670/167
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1671/167
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1670/167
Most frequent other events
Showing 10 of 56
Most frequent other events
EventNGM/25mcg EEDRSP/20mcg EE
Mood swingsPsychiatric disorders3/1675/167
IrritabilityGeneral disorders1/1674/167
NauseaGastrointestinal disorders4/1671/167
AcneSkin and subcutaneous tissue disorders0/1673/167
Pharyngitis streptococcalInfections and infestations3/1670/167
SinusitisInfections and infestations3/1670/167
Back painMusculoskeletal and connective tissue disorders1/1672/167
Breast tendernessReproductive system and breast disorders2/1670/167
DysmenorrheaReproductive system and breast disorders0/1672/167
HeadacheNervous system disorders2/1672/167

Baseline characteristics

Age, Customized
Age, Customized(participants)NGM/25mcg EEDRSP/20mcg EETotal
<18 years000
>= 18 and < 65 years178177355
>=65 years000
Age, Continuous
Age, Continuous(years)NGM/25mcg EEDRSP/20mcg EETotal
Mean27.2 ± 6.7027.2 ± 6.5227.2 ± 6.60
Sex: Female, Male
Sex: Female, Male(Participants)NGM/25mcg EEDRSP/20mcg EETotal
Female178177355
Male000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kaunitz AM, Burkman RT, Fisher AC, LaGuardia KD. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial. Obstet Gynecol. 2009 Dec;114(6):1205-1212. doi: 10.1097/AOG.0b013e3181beab47. PubMed 19935020 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2010, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2008
First posted
Sep 3, 2008
Start
May 2008
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
May 25, 2010
Last update
Mar 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00745901
Responsible party
Sponsor
First posted
Sep 3, 2008
Start date
May 2008
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
May 25, 2010
Last update
Mar 19, 2019

Study contacts

Ortho-McNeil Janssen Scientific Affairs, LLC Clinical Trial
study director · Ortho-McNeil Janssen Scientific Affairs, LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Norgestimate · Ethinyl Estradiol · Drospirenone

Start the discussion